Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 79 articles: HTML format

Single Articles

March 2024
1. MOIK F, Riedl JM, Ay C
   Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
   Ann Oncol. 2024;35:327.
   PubMed    
   
   
   
2. PASSARO A, Wang J, Shah S, Bauml JM, et al
   Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl
   Ann Oncol. 2024;35:328-329.
   PubMed    
   
   
   February 2024
3. ROLFO C, Russo A
   Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer.
   Ann Oncol. 2024;35:147-149.
   PubMed    
   
   
   January 2024
4. SANTUCCI C, Mignozzi S, Malvezzi M, Boffetta P, et al
   European cancer mortality predictions for the year 2024 with focus on colorectal cancer.
   Ann Oncol. 2024 Jan 17:S0923-7534(23)05110-4. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   
5. BUROTTO M, Zvirbule Z, Mochalova A, Runglodvatana Y, et al
   Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally a
   Ann Oncol. 2024 Jan 8:S0923-7534(23)05112-8. doi: 10.1016/j.annonc.2023.
   PubMed    
   
   
   
6. PASSARO A, Wang J, Wang Y, Lee SH, et al
   Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
   Ann Oncol. 2024;35:77-90.
   PubMed     Abstract available
   
   
   
7. PRELAJ A, Miskovic V, Zanitti M, Trovo F, et al
   Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review.
   Ann Oncol. 2024;35:29-65.
   PubMed     Abstract available
   
   
   December 2023
8. FULTON-WARD T, Middleton G
   The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.
   Ann Oncol. 2023;34:1113-1130.
   PubMed     Abstract available
   
   
   November 2023
9. TRAN HT, Heeke S, Sujit S, Vokes N, et al
   Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small cell lung cancer.
   Ann Oncol. 2023 Nov 20:S0923-7534(23)05072-X. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   
10. SHIRAISHI Y, Sekino Y, Horinouchi H, Ohe Y, et al
    High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab.
    Ann Oncol. 2023;34:1064-1065.
    PubMed    
    
    
    October 2023
11. BORGHAEI H, de Marinis F, Dumoulin D, Reynolds C, et al
    SAPPHIRE: Phase III Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Advanced Non-Squamous Non-Small Cell Lung Cancer.
    Ann Oncol. 2023 Oct 11:S0923-7534(23)04019-X. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
12. JOHN A, Popat S
    Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?
    Ann Oncol. 2023;34:829-830.
    PubMed    
    
    
    
13. GOUDA MA, Hu MI, Cabanillas ME, Wu J, et al
    Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors.
    Ann Oncol. 2023;34:946-948.
    PubMed    
    
    
    August 2023
14. BESSE B, Felip E, Campelo RG, Cobo M, et al
    Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.
    Ann Oncol. 2023 Aug 1:S0923-7534(23)00790-1. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    July 2023
15. FELIP E, Altorki N, Zhou C, Vallieres E, et al
    Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
    Ann Oncol. 2023 Jul 17:S0923-7534(23)00764-0. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
16. BOIARSKY D, Lydon CA, Chambers ES, Sholl LM, et al
    Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
    Ann Oncol. 2023;34:589-604.
    PubMed     Abstract available
    
    
    
17. RAKAEE M, Andersen S, Giannikou K, Paulsen EE, et al
    Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.
    Ann Oncol. 2023;34:578-588.
    PubMed     Abstract available
    
    
    June 2023
18. BAZHENOVA L
    Corrigendum to "Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level": [Annals of Oncology 34 (2023) 327-332].
    Ann Oncol. 2023 Jun 7:S0923-7534(23)00688-9. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    May 2023
19. BUROTTO M, Zvirbule Z, Mochalova A, Runglodvatana Y, et al
    IMscin001 Part 2: A randomised phase III, open-label, multicentre study examining the pharmacokinetics (PK), efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous in previously treated locally advanced or metastatic non-
    Ann Oncol. 2023 May 31:S0923-7534(23)00694-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
20. CHOUAID C, Gendarme S, Auliac JB
    Artificial intelligence to finally enable precision medicine for the management of resected non-small cell lung cancer.
    Ann Oncol. 2023 May 12:S0923-7534(23)00675-0. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    April 2023
21. BAZHENOVA L
    Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level.
    Ann Oncol. 2023;34:327-332.
    PubMed    
    
    
    
22. MOK TSK, Lopes G, Cho BC, Kowalski DM, et al
    Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Ann Oncol. 2023;34:377-388.
    PubMed     Abstract available
    
    
    March 2023
23. SCALERA S, Ricciuti B, Mazzotta M, Calonaci N, et al
    Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
    Ann Oncol. 2023;34:275-288.
    PubMed     Abstract available
    
    
    February 2023
24. REMON J, Besse B, Aix SP, Callejo A, et al
    Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
    Ann Oncol. 2023 Feb 28:S0923-7534(23)00089-3. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    January 2023
25. MALVEZZI M, Santucci C, Boffetta P, Collatuzzo G, et al
    EUROPEAN CANCER MORTALITY PREDICTIONS FOR THE YEAR 2023 WITH FOCUS ON LUNG CANCER.
    Ann Oncol. 2023 Jan 27:S0923-7534(23)00048-0. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
26. HENDRIKS LE, Kerr KM, Menis J, Mok TS, et al
    Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
    Ann Oncol. 2023 Jan 23:S0923-7534(22)04781-0. doi: 10.1016/j.annonc.2022.
    PubMed    
    
    
    
27. HENDRIKS LE, Kerr KM, Menis J, Mok TS, et al
    Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2023 Jan 3:S0923-7534(22)04785-8. doi: 10.1016/j.annonc.2022.
    PubMed    
    
    
    
28. REICHERT ZR, Morgan TM, Li G, Castellanos E, et al
    Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.
    Ann Oncol. 2023;34:111-120.
    PubMed     Abstract available
    
    
    December 2022
29. SELENICA P, Marra A, Choudhury NJ, Gazzo A, et al
    APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
    Ann Oncol. 2022;33:1284-1295.
    PubMed     Abstract available
    
    
    November 2022
30. BORGHAEI H, Ciuleanu TE, Lee JS, Pluzanski A, et al
    Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis.
    Ann Oncol. 2022 Nov 19:S0923-7534(22)04740-8. doi: 10.1016/j.annonc.2022.
    PubMed     Abstract available
    
    
    
31. CORTELLINI A, Barrichello APC, Alessi JV, Ricciuti B, et al
    A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions.
    Ann Oncol. 2022;33:1202-1204.
    PubMed    
    
    
    
32. MCGRAIL DJ, Pilie PG, Rashid NU, Voorwerk L, et al
    Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.
    Ann Oncol. 2022;33:1204-1206.
    PubMed    
    
    
    October 2022
33. PEYRAUD F, Guegan JP, Bodet D, Nafia I, et al
    Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
    Ann Oncol. 2022;33:1041-1051.
    PubMed     Abstract available
    
    
    September 2022
34. DIMITRIOU F, Namikawa K, Reijers ILM, Buchbinder EI, et al
    Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
    Ann Oncol. 2022;33:968-980.
    PubMed     Abstract available
    
    
    August 2022
35. GRIESINGER F, Curigliano G, Thomas M, Subbiah V, et al
    Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial.
    Ann Oncol. 2022 Aug 13. pii: S0923-7534(22)03866.
    PubMed     Abstract available
    
    
    
36. LUO J, Wu S, Rizvi H, Zhang Q, et al
    Deciphering radiological stable disease to immune checkpoint inhibitors.
    Ann Oncol. 2022;33:824-835.
    PubMed     Abstract available
    
    
    
37. ZHANG FL, Song SS, Wang J, Zhang P, et al
    First-generation EGFR-TKI in refractory metastatic alveolar soft part sarcoma with EGFR alteration: a case report.
    Ann Oncol. 2022;33:847-848.
    PubMed    
    
    
    July 2022
38. RICCIUTI B, Alessi JV, Elkrief A, Wang X, et al
    Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D) mutated non-small cell lung cancer.
    Ann Oncol. 2022 Jul 21. pii: S0923-7534(22)01856.
    PubMed     Abstract available
    
    
    
39. SHAO XM, Huang J, Niknafs N, Balan A, et al
    HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
    Ann Oncol. 2022;33:728-738.
    PubMed     Abstract available
    
    
    June 2022
40. CORTIULA F, Reymen B, Peters S, Van Mol P, et al
    Immunotherapy in unresectable stage III non-small cell lung cancer: state of the art and novel therapeutic approaches.
    Ann Oncol. 2022 Jun 28. pii: S0923-7534(22)01742.
    PubMed     Abstract available
    
    
    
41. BRUNET M, Crombe A, Cousin S, Vanhersecke L, et al
    Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small cell lung cancer.
    Ann Oncol. 2022 Jun 25. pii: S0923-7534(22)01736.
    PubMed    
    
    
    May 2022
42. CEDRES S, Felip E
    3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma.
    Ann Oncol. 2022;33:457-459.
    PubMed    
    
    
    
43. SUBBIAH V, Iannotti NO, Gutierrez M, Smith DC, et al
    FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Ann Oncol. 2022;33:522-533.
    PubMed     Abstract available
    
    
    
44. PETERS S, Scherpereel A, Cornelissen R, Oulkhouir Y, et al
    First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
    Ann Oncol. 2022;33:488-499.
    PubMed     Abstract available
    
    
    April 2022
45. CHEN J, Facchinetti F, Braye F, Yurchenko AA, et al
    Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
    Ann Oncol. 2022;33:434-444.
    PubMed     Abstract available
    
    
    March 2022
46. ROSELL R, Cardona AF, Arrieta O, Gonzalez-Cao M, et al
    Classification of atypical EGFR mutations in non-small cell lung cancer.
    Ann Oncol. 2022 Mar 21. pii: S0923-7534(22)00389.
    PubMed    
    
    
    
47. JANNING M, Suptitz J, Albers-Leischner C, Delpy P, et al
    Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).
    Ann Oncol. 2022 Mar 6. pii: S0923-7534(22)00361.
    PubMed     Abstract available
    
    
    February 2022
48. GALE D, Heider K, Ruiz-Valdepenas A, Hackinger S, et al
    Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Ann Oncol. 2022 Feb 26. pii: S0923-7534(22)00123.
    PubMed     Abstract available
    
    
    
49. PEROL M, Felip E, Dafni U, Polito L, et al
    Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data.
    Ann Oncol. 2022 Feb 23. pii: S0923-7534(22)00124.
    PubMed     Abstract available
    
    
    
50. PASSARO A, Leighl N, Blackhall F, Popat S, et al
    ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.
    Ann Oncol. 2022 Feb 14. pii: S0923-7534(22)00112.
    PubMed     Abstract available
    
    
    
51. REMON J, Hendriks LEL, Bironzo P
    Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease.
    Ann Oncol. 2022;33:123-125.
    PubMed    
    
    
    
52. POPAT S, Baas P, Faivre-Finn C, Girard N, et al
    Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up().
    Ann Oncol. 2022;33:129-142.
    PubMed    
    
    
    
53. SOO RA, Han JY, Dafni U, Cho BC, et al
    A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER tria
    Ann Oncol. 2022;33:181-192.
    PubMed     Abstract available
    
    
    January 2022
54. PASTORINO U, Boeri M, Sestini S, Sabia F, et al
    Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial.
    Ann Oncol. 2022 Jan 25. pii: S0923-7534(22)00017.
    PubMed     Abstract available
    
    
    
55. NOVELLO S, Torri V, Grohe C, Kurz S, et al
    Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-
    Ann Oncol. 2022 Jan 24. pii: S0923-7534(22)00014.
    PubMed    
    
    
    
56. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    PubMed     Abstract available
    
    
    
57. KOK IC, Hooiveld JS, van de Donk PP, Giesen D, et al
    (89)Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.
    Ann Oncol. 2022;33:80-88.
    PubMed     Abstract available
    
    
    December 2021
58. WAUTERS E, Vansteenkiste J
    Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding.
    Ann Oncol. 2021;32:1463-1465.
    PubMed    
    
    
    
59. TOPP BG, Thiagarajan K, De Alwis DP, Snyder A, et al
    Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab.
    Ann Oncol. 2021;32:1618-1625.
    PubMed     Abstract available
    
    
    November 2021
60. ATTILI I, Passaro A, de Marinis F
    Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials.
    Ann Oncol. 2021 Nov 25. pii: S0923-7534(21)04823.
    PubMed    
    
    
    
61. NIU J, Maurice-Dror C, Lee DH, Kim DW, et al
    First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer.
    Ann Oncol. 2021 Nov 17. pii: S0923-7534(21)04776.
    PubMed     Abstract available
    
    
    October 2021
62. CHOW A, Hellmann MD
    Insights from prospective multi-omic profiling of lymphocytes in resected lung cancer.
    Ann Oncol. 2021 Oct 26. pii: S0923-7534(21)04549.
    PubMed    
    
    
    
63. FEDERICO L, McGrail DJ, Bentebibel SE, Haymaker C, et al
    Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer.
    Ann Oncol. 2021 Oct 12. pii: S0923-7534(21)04519.
    PubMed     Abstract available
    
    
    
64. NOVELLO S, Torri V, Grohe C, Kurz S, et al
    International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung
    Ann Oncol. 2021 Oct 5. pii: S0923-7534(21)04496.
    PubMed     Abstract available
    
    
    
65. SHITARA K, Lunceford J
    Response to the letter to the Editor: TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061.
    Ann Oncol. 2021;32:1303-1304.
    PubMed    
    
    
    September 2021
66. PETERS S, Pujol JL, Dafni U, Domine M, et al
    Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
    Ann Oncol. 2021 Sep 22. pii: S0923-7534(21)04490.
    PubMed     Abstract available
    
    
    
67. DICKSON JL, Horst C, Nair A, Tisi S, et al
    Hesitancy around low dose CT screening for lung cancer.
    Ann Oncol. 2021 Sep 20. pii: S0923-7534(21)04487.
    PubMed     Abstract available
    
    
    
68. SCHOENFELD AJ, Antonia SJ, Awad MM, Felip E, et al
    Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer.
    Ann Oncol. 2021 Sep 3. pii: S0923-7534(21)04455.
    PubMed     Abstract available
    
    
    
69. SAW SPL, Tan DSW
    Co-targeting the VEGF axis and immune checkpoints in NSCLC: back to the future.
    Ann Oncol. 2021;32:1075-1076.
    PubMed    
    
    
    
70. FOOTE MB, Maron SB, Cercek A, Argiles G, et al
    TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061.
    Ann Oncol. 2021;32:1188-1189.
    PubMed    
    
    
    August 2021
71. REMON J, Soria JC, Peters S
    Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.
    Ann Oncol. 2021 Aug 28. pii: S0923-7534(21)04279.
    PubMed    
    
    
    
72. CORTELLINI A, Ricciuti B, Facchinetti F, Alessi JVM, et al
    Antibiotic-exposed patients with non-small cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
    Ann Oncol. 2021 Aug 13. pii: S0923-7534(21)03973.
    PubMed     Abstract available
    
    
    July 2021
73. RODRIGUEZ-ABREU D, Powell SF, Hochmair MJ, Gadgeel S, et al
    Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
    Ann Oncol. 2021;32:881-895.
    PubMed     Abstract available
    
    
    June 2021
74. SUGAWARA S, Lee JS, Kang JH, Kim HR, et al
    Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ann Oncol. 2021 Jun 14. pii: S0923-7534(21)02052.
    PubMed     Abstract available
    
    
    
75. RECK M, Carbone DP, Garassino M, Barlesi F, et al
    Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.
    Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02045.
    PubMed     Abstract available
    
    
    
76. BARDIA A, Messersmith WA, Kio EA, Berlin JD, et al
    Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
    Ann Oncol. 2021;32:746-756.
    PubMed     Abstract available
    
    
    May 2021
77. BLACKHALL FH
    Reframing recalcitrance for small cell lung cancer.
    Ann Oncol. 2021 May 3. pii: S0923-7534(21)01186.
    PubMed    
    
    
    
78. LACH KD, Sorin M, Huynh C, Alirezaie NS, et al
    Combined small-cell lung carcinoma revealed to be an intratumoural metastasis by genetic analysis.
    Ann Oncol. 2021;32:679-681.
    PubMed    
    
    
    April 2021
79. DINGEMANS AC, Fruh M, Ardizzoni A, Besse B, et al
    Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2021 Apr 9. pii: S0923-7534(21)01113.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.